Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a component of certain pneumococcal conjugate vaccines. It consists of the purified capsular polysaccharide from Streptococcus pneumoniae serotype 15B, chemically linked (conjugated) to a nontoxic variant of diphtheria toxin known as CRM197. This conjugation enhances immunogenicity by inducing a T-cell dependent immune response, leading to improved antibody production and immunological memory compared to unconjugated (polysaccharide-only) vaccines[1][3][8]. The primary indication is for active immunization against invasive pneumococcal disease and pneumonia caused by S. pneumoniae serotype 15B[2][5]. This antigen may be included in multivalent pneumococcal vaccines such as PCV20 or PCV21, which are designed for broader protection against multiple S. pneumoniae serotypes[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen.